These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23553898)

  • 21. Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints.
    Rauch G; Kieser M; Binder H; Bayes-Genis A; Jahn-Eimermacher A
    Clin Res Cardiol; 2018 May; 107(5):437-443. PubMed ID: 29453594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opportunities and challenges of clinical trials in cardiology using composite primary endpoints.
    Rauch G; Rauch B; Schüler S; Kieser M
    World J Cardiol; 2015 Jan; 7(1):1-5. PubMed ID: 25632312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
    Roig MB; Melis GG; Posch M; Koenig F
    Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Some issues with composite endpoints in clinical trials.
    Chi GY
    Fundam Clin Pharmacol; 2005 Dec; 19(6):609-19. PubMed ID: 16313272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
    Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of composite endpoints in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2014 Nov; 33(27):4709-14. PubMed ID: 24833282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF; Lyle PA;
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints.
    Lafaye de Micheaux P; Liquet B; Marque S; Riou J
    J Biopharm Stat; 2014; 24(2):378-97. PubMed ID: 24605975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A weighted combined effect measure for the analysis of a composite time-to-first-event endpoint with components of different clinical relevance.
    Rauch G; Kunzmann K; Kieser M; Wegscheider K; König J; Eulenburg C
    Stat Med; 2018 Feb; 37(5):749-767. PubMed ID: 29205425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size estimation for non-inferiority trials of time-to-event data.
    Crisp A; Curtis P
    Pharm Stat; 2008; 7(4):236-44. PubMed ID: 17583558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical grand rounds: design and analysis of studies with binary- event composite endpoints: guidelines for anesthesia research.
    Mascha EJ; Sessler DI
    Anesth Analg; 2011 Jun; 112(6):1461-71. PubMed ID: 21543784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.
    Friede T; Schmidli H
    Stat Med; 2010 May; 29(10):1145-56. PubMed ID: 20146203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accrual by groups in trials with discrete-time survival endpoints.
    Jóźwiak K; Moerbeek M
    Clin Trials; 2013 Feb; 10(1):32-42. PubMed ID: 23203992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.